SecBot SecBot
SECBOTREPLAY Home › Report › RVMD

RVMD · Revolution Medicines announced two concurrent capital raises: a $750…

Revolution Medicines, Inc. · PRESS-RELEASE filed Apr 13, 2026 at 16:01 ET

At the news

BEARISHIMPACT 7/10

PRESS-RELEASE filed Apr 13, 2026 at 16:01 ET

Revolution Medicines announced two concurrent capital raises: a $750 million common stock offering and a $250 million convertible note offering due 2033, with over-allotment options totaling $150 million. The offerings are not contingent on each other, and proceeds will fund R&D and potential commercialization of its RAS-targeted oncology pipeline.

  • Company is conducting a $750 million common stock offering and a $250 million convertible senior notes offering due 2033.
  • Underwriters have 30-day options to purchase up to an additional $112.5 million in stock and $37.5 million in notes.
  • Offerings are not contingent on each other.
  • Net proceeds will be used for R&D, commercialization planning, general corporate purposes, and capital expenditures.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access